FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165220706> ?p ?o ?g. }

• W3165220706 endingPage "3170" @default.
• W3165220706 startingPage "3161" @default.
• W3165220706 abstract "PURPOSE Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care for adult acute promyelocytic leukemia (APL). However, the safety and effectiveness of this treatment in pediatric patients with APL have not been reported on the basis of larger sample sizes. METHODS We conducted a multicenter trial at 38 hospitals in China. Patients with newly diagnosed APL were stratified into two risk groups according to baseline WBC count and FLT3-ITD mutation. ATRA plus arsenic trioxide or oral arsenic without chemotherapy were administered to the standard-risk group, whereas ATRA, arsenic trioxide, or oral arsenic plus reduced-dose anthracycline were administered to the high-risk group. Primary end points were event-free survival and overall survival at 2 years. RESULTS We enrolled 193 patients with APL. After a median follow-up of 28.9 months, the 2-year overall survival rate was 99% (95% CI, 97 to 100) in the standard-risk group and 95% (95% CI, 90 to 100) in the high-risk group ( P = .088). The 2-year event-free survival was 97% (95% CI, 93 to 100) in the standard-risk group and 90% (95% CI, 83 to 96) in the high-risk group ( P = .252). The plasma levels of arsenic were significantly elevated after treatment, with a stable effective level ranging from 42.9 to 63.2 ng/mL during treatment. In addition, plasma, urine, hair, and nail arsenic levels rapidly decreased to normal 6 months after the end of treatment. CONCLUSION Arsenic combined with ATRA is effective and safe in pediatric patients with APL, although long-term follow-up is still needed." @default.
• W3165220706 created "2021-06-07" @default.
• W3165220706 creator A5001225824 @default.
• W3165220706 creator A5001979626 @default.
• W3165220706 creator A5002188808 @default.
• W3165220706 creator A5003246532 @default.
• W3165220706 creator A5004086293 @default.
• W3165220706 creator A5006300126 @default.
• W3165220706 creator A5007743379 @default.
• W3165220706 creator A5008121592 @default.
• W3165220706 creator A5012278873 @default.
• W3165220706 creator A5014676719 @default.
• W3165220706 creator A5019631045 @default.
• W3165220706 creator A5020865157 @default.
• W3165220706 creator A5020923838 @default.
• W3165220706 creator A5029599797 @default.
• W3165220706 creator A5029966161 @default.
• W3165220706 creator A5030513531 @default.
• W3165220706 creator A5033489919 @default.
• W3165220706 creator A5033718291 @default.
• W3165220706 creator A5034833979 @default.
• W3165220706 creator A5036392227 @default.
• W3165220706 creator A5037458498 @default.
• W3165220706 creator A5037796472 @default.
• W3165220706 creator A5038004888 @default.
• W3165220706 creator A5038832637 @default.
• W3165220706 creator A5044084703 @default.
• W3165220706 creator A5044756293 @default.
• W3165220706 creator A5051318920 @default.
• W3165220706 creator A5055160753 @default.
• W3165220706 creator A5055585688 @default.
• W3165220706 creator A5059841532 @default.
• W3165220706 creator A5060813775 @default.
• W3165220706 creator A5062161921 @default.
• W3165220706 creator A5068056188 @default.
• W3165220706 creator A5069804526 @default.
• W3165220706 creator A5070166399 @default.
• W3165220706 creator A5071092152 @default.
• W3165220706 creator A5075095992 @default.
• W3165220706 creator A5077603488 @default.
• W3165220706 creator A5079025262 @default.
• W3165220706 creator A5082600835 @default.
• W3165220706 creator A5083967189 @default.
• W3165220706 creator A5084971221 @default.
• W3165220706 creator A5085338214 @default.
• W3165220706 creator A5085540883 @default.
• W3165220706 creator A5086783677 @default.
• W3165220706 creator A5088034304 @default.
• W3165220706 creator A5091660239 @default.
• W3165220706 date "2021-10-01" @default.
• W3165220706 modified "2023-10-10" @default.
• W3165220706 title "Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study" @default.
• W3165220706 cites W1531493896 @default.
• W3165220706 cites W1622548798 @default.
• W3165220706 cites W1826104083 @default.
• W3165220706 cites W1948328750 @default.
• W3165220706 cites W1965141571 @default.
• W3165220706 cites W1982745688 @default.
• W3165220706 cites W2008790407 @default.
• W3165220706 cites W2010216204 @default.
• W3165220706 cites W2023546573 @default.
• W3165220706 cites W2072219402 @default.
• W3165220706 cites W2089988981 @default.
• W3165220706 cites W2102362614 @default.
• W3165220706 cites W2129338773 @default.
• W3165220706 cites W2155717682 @default.
• W3165220706 cites W2160296569 @default.
• W3165220706 cites W2169503443 @default.
• W3165220706 cites W2292214970 @default.
• W3165220706 cites W2319804622 @default.
• W3165220706 cites W2325915923 @default.
• W3165220706 cites W2337147024 @default.
• W3165220706 cites W2472473799 @default.
• W3165220706 cites W2561289538 @default.
• W3165220706 cites W2725930552 @default.
• W3165220706 cites W2739607402 @default.
• W3165220706 cites W2789467971 @default.
• W3165220706 cites W2800205232 @default.
• W3165220706 cites W2806637980 @default.
• W3165220706 cites W2889022305 @default.
• W3165220706 cites W2918095490 @default.
• W3165220706 cites W2945659286 @default.
• W3165220706 cites W2954028758 @default.
• W3165220706 cites W2973363925 @default.
• W3165220706 cites W2986834274 @default.
• W3165220706 cites W4293300006 @default.
• W3165220706 doi "https://doi.org/10.1200/jco.20.03096" @default.
• W3165220706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8478377" @default.
• W3165220706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34077242" @default.
• W3165220706 hasPublicationYear "2021" @default.
• W3165220706 type Work @default.
• W3165220706 sameAs 3165220706 @default.
• W3165220706 citedByCount "17" @default.
• W3165220706 countsByYear W31652207062021 @default.
• W3165220706 countsByYear W31652207062022 @default.
• W3165220706 countsByYear W31652207062023 @default.
• W3165220706 crossrefType "journal-article" @default.
• W3165220706 hasAuthorship W3165220706A5001225824 @default.

• next